TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20011881

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 24 g in 250 ml saline solution
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (250 ml saline solution)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 17501866

Group type: EXPERIMENTAL
Intervention: Primary repair (augmented or non-augmented)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early ACL repair or reconstruction
Number of subjects: 100
Study: 15141917

Group type: EXPERIMENTAL
Intervention: Experimental group received verbal instructions on phoneme production and used a tongue blade for lingual awareness
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group received instructions in articulatory placement only
Number of subjects: 40
Study: 11604268

Group type: EXPERIMENTAL
Intervention: Citric acid added to enteric-coated matrix granules and tablet matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without citric acid)
Number of subjects: 0
Study: 9819787

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (Premarin) 0.625 mg/day orally plus medroxyprogesterone acetate (Farlutal) 10 mg/day orally (RHRT group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: No medication (NRHRT group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: NRHRT and RHRT groups
Number of subjects: 55

Group type: COMPARATOR
Intervention: Premenopausal healthy subjects (PreM group)
Number of subjects: 55
Study: 7650533

Group type: EXPERIMENTAL
Intervention: Type II fiber atrophy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Skeletal myopathy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Alcoholic cardiomyopathy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Peripheral neuropathy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cirrhosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total lifetime dose of ethanol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Percentage of ideal body weight and lean body mass
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Caloric malnutrition
Number of subjects: 100
Study: 2523660

Group type: EXPERIMENTAL
Intervention: 10 mg oral isradipine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Isradipine treatment over 12 weeks
Number of subjects: 9
Study: 848803

Group type: EXPERIMENTAL
Intervention: Ragweed inhalation challenge
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mecholyl bronchospastic response
Number of subjects: 26

Group type: COMPARATOR
Intervention: Negative ragweed challenge
Number of subjects: 26
Study: 31808584

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fluoride varnish (FV)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combination of LLLT and fluoride varnish (L + FV)
Number of subjects: 66
Study: 31377287

Group type: EXPERIMENTAL
Intervention: Micro-Stent implantation plus phacoemulsification
Number of subjects: 282

Group type: COMPARATOR
Intervention: Phacoemulsification alone (Control)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Micro-Stent group
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 282
Study: 29077812

Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 2% milk
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ensure Clear
Number of subjects: 48
Study: 24832696

Group type: EXPERIMENTAL
Intervention: Cross-pin fixation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Metal interference screw fixation
Number of subjects: 62
Study: 23194841

Group type: EXPERIMENTAL
Intervention: Intense counseling (nutrition education materials included)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Normal counseling (individualized dietary program)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intense counseling
Number of subjects: 89

Group type: COMPARATOR
Intervention: Normal counseling
Number of subjects: 89
Study: 21252704

Group type: EXPERIMENTAL
Intervention: Deeper anesthesia (n = 50)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lighter anesthesia (n = 46)
Number of subjects: 96
Study: 17611792

Group type: EXPERIMENTAL
Intervention: Doxorubicin and docetaxel (AD)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Doxorubicin and paclitaxel (AP)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Doxorubicin and taxane combinations (both arms)
Number of subjects: 210
Study: 16830018

Group type: COMPARATOR
Intervention: Propofol 1% alone (Control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Propofol 1% premixed with 40 mg of lidocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Propofol 1% given 60 seconds after 40 mg of lidocaine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Venous occlusion for 60 seconds with lidocaine 1% (40 mg) followed by propofol
Number of subjects: 200
Study: 15477438

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 1262
Study: 11049104

Group type: EXPERIMENTAL
Intervention: TCV-309
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 9350846

Group type: EXPERIMENTAL
Intervention: NO-GO condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: GO condition
Number of subjects: 10
Study: 7901024

Group type: EXPERIMENTAL
Intervention: Fenspiride hydrochloride (80 mg) administered IV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenspiride hydrochloride (80 mg) administered orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenspiride hydrochloride (IV and oral)
Number of subjects: 12
Study: 3535976

Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29406835

Group type: EXPERIMENTAL
Intervention: Nonthrust manipulation (NTM)
Number of subjects: 103
Study: 26895001

Group type: EXPERIMENTAL
Intervention: Tumescent lidocaine without liposuction at a dosage of 28 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tumescent lidocaine with liposuction at a dosage of 45 mg/kg
Number of subjects: 14
Study: 24889008

Group type: EXPERIMENTAL
Intervention: Behavioral/educational intervention
Number of subjects: 300
Study: 23613810

Group type: EXPERIMENTAL
Intervention: L-Dopa
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DRD2/ANKK1 genotype
Number of subjects: 50
Study: 19939354

Group type: EXPERIMENTAL
Intervention: Low cost micro-camera
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic camera
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Trained groups (both cameras)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-trained groups
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Surgeons
Number of subjects: 48

Group type: COMPARATOR
Intervention: Students
Number of subjects: 48
Study: 19014156

Group type: EXPERIMENTAL
Intervention: Flapless immediately loaded implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional implants (submerged or unsubmerged)
Number of subjects: 40
Study: 16898534

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (13 age- and sex-matched individuals)
Number of subjects: 16
Study: 12683470

Group type: EXPERIMENTAL
Intervention: Nefazodone (300-600 mg per day in two divided doses)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Psychotherapy (16-20 sessions of CBASP)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Combination of nefazodone and psychotherapy
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Nefazodone (alone or in combination with CBASP)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 484
Study: 11081319

Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 9592270

Group type: EXPERIMENTAL
Intervention: Gluma dentin bonding (experimental group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Durafill bonding (control group)
Number of subjects: 19
Study: 1532672

Group type: EXPERIMENTAL
Intervention: FUDR (0.05 to 1.7 mg/kg/d) alone or combined with 5-FU and leucovorin
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: FUDR, 5-FU, and leucovorin
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Combined intraarterial treatment with LCV
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Regional treatment
Number of subjects: 221
Study: 2992278

Group type: EXPERIMENTAL
Intervention: Estradiol transdermal system, 0.1 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conjugated equine estrogens, 0.625 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conjugated equine estrogens, 1.25 mg/day
Number of subjects: 124
Study: 31373648

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus S‐1 and oxaliplatin
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo plus S‐1 and oxaliplatin
Number of subjects: 189
Study: 27666380

Group type: EXPERIMENTAL
Intervention: nuts, seeds, fruit, and fish dietary pattern
Number of subjects: 328
Study: 26725556

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 23830709

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT) targeted to the C5‐C6 spinal segment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham spinal manipulative therapy
Number of subjects: 33
Study: 21830515

Group type: EXPERIMENTAL
Intervention: 200 ms display delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral vision occluded
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Image scale factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delay
Number of subjects: 0
Study: 19285849

Group type: EXPERIMENTAL
Intervention: Mouth taping at night
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual breathing at night
Number of subjects: 51
Study: 16708309

Group type: EXPERIMENTAL
Intervention: Full intervention (communication training)
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Limited intervention (evidence-based guidelines only)
Number of subjects: 837

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 837
Study: 15641877

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 12221393

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX) gel
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (CHX) solution
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 2% CHX solution + a 25% CHX‐containing controlled‐release device
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ca(OH)(2)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ca(OH)(2)+ 0.2% CHX gel
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0.2% CHX gel
Number of subjects: 98

Group type: COMPARATOR
Intervention: saline
Number of subjects: 98

Group type: COMPARATOR
Intervention: gel vehicle
Number of subjects: 98
Study: 9891196

Group type: EXPERIMENTAL
Intervention: Leukocyte-interferon-alpha, 6 MU three times a week for 4 months, followed by 3 MU three times a week for 8 months (Group I)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Recombinant-IFN-alpha-2a, with the same schedule (Group II)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Lymphoblastoid-IFN-alpha-N1, with the same schedule (Group III)
Number of subjects: 107
Study: 7976413

Group type: EXPERIMENTAL
Intervention: Metyrapone (11 beta‐hydroxylase inhibitor) followed by growth hormone releasing hormone (1 microgram kg‐1 body wt)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo followed by growth hormone releasing hormone (1 microgram kg‐1 body wt)
Number of subjects: 6
Study: 3076139

Group type: EXPERIMENTAL
Intervention: Pinacidil
Number of subjects: 0
Study: 31385741

Group type: EXPERIMENTAL
Intervention: Third-party assessment of complications
Number of subjects: 429

Group type: COMPARATOR
Intervention: Primary registration in the Swedish Cystectomy Registry
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Third-party assessment
Number of subjects: 429

Group type: COMPARATOR
Intervention: Primary registration
Number of subjects: 429
Study: 29095263

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.5 mL/kg/h, 5 mg/50 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study: 25992505

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding (40 to 60% of calculated caloric requirements)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Standard enteral feeding (70 to 100% of calculated caloric requirements)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 894

Group type: COMPARATOR
Intervention: Standard enteral feeding
Number of subjects: 894
Study: 23602862

Group type: EXPERIMENTAL
Intervention: Lowest quartile of 25(OH)D concentrations
Number of subjects: 4233

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentrations
Number of subjects: 4233
Study: 21911632

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 703

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 703
Study: 19735542

Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) care with seven treatment sessions from two different types of complementary therapies over ten weeks.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Integrative Medicine (IM) care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional care (advice and prescription of analgesics)
Number of subjects: 80
Study: 16434256

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 32

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 15133637

Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration biopsy (FNA)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: MIBI scans
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Frozen section biopsy (FS)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combined use of FNA, MIBI, and FS
Number of subjects: 130
Study: 11600538

Group type: EXPERIMENTAL
Intervention: Sufficient endogenous GH
Number of subjects: 250

Group type: COMPARATOR
Intervention: GH deficiency
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Healthy adolescents (both boys and girls)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Healthy adolescents (ages 17-21)
Number of subjects: 250
Study: 9028311

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with fractionated total body irradiation, etoposide (VP) 60 mg/kg, and cyclophosphamide (Cy) 100 mg/kg.
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with BCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous hematopoietic progenitor cell transplantation with CCNU 15 mg/kg, VP 60 mg/kg, and Cy 100 mg/kg.
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Patients with none of the unfavorable prognostic factors (systemic symptoms at relapse, disseminated pulmonary or bone marrow disease at relapse, and more than minimal disease at the time of transplantation).
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Patients with one or more unfavorable prognostic factors.
Number of subjects: 119
Study: 8330870

Group type: EXPERIMENTAL
Intervention: Octreotide (Sandostatin, Sandoz, Switzerland)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BIM 23014 (Lanreotide, Ipsen Biotech, France)
Number of subjects: 10
Study: 2438451

Group type: EXPERIMENTAL
Intervention: Middle-molecular weight hydroxyethyl starch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular weight dextran solution
Number of subjects: 0
Study: 31298289

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perineural PRP injection and medical treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 60
Study: 28786698

Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 0
Study: 27298527

Group type: EXPERIMENTAL
Intervention: Intrauterine 2% lignocaine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 84
Study: 26654906

Group type: EXPERIMENTAL
Intervention: Microbial cell preparation (daily dosage of 6 × 10^10 CFU)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 23532097

Group type: EXPERIMENTAL
Intervention: Cobicistat (COBI)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Ritonavir (RTV)
Number of subjects: 692
Study: 20950389

Group type: EXPERIMENTAL
Intervention: Low-intensity stepped care intervention aimed at reducing depressive symptoms
Number of subjects: 114

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 114
Study: 18227766

Group type: EXPERIMENTAL
Intervention: Nonpenetrating very deep sclerectomy (NPVDS) with reticulated hyaluronic acid implant (SKGEL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonpenetrating deep sclerectomy (NPDS)
Number of subjects: 50
Study: 16595356

Group type: EXPERIMENTAL
Intervention: Brief intervention for T‐ACE positive women
Number of subjects: 51

Group type: COMPARATOR
Intervention: T‐ACE negative group
Number of subjects: 51

Group type: COMPARATOR
Intervention: T‐ACE positive group
Number of subjects: 51
Study: 15374551

Group type: EXPERIMENTAL
Intervention: ETT cuff inflated to achieve sealing pressure (Pseal group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ETT cuff inflated to achieve a pressure of 25 cm H2O (P25 group)
Number of subjects: 50
Study: 11298610

Group type: EXPERIMENTAL
Intervention: 75 microg/kg/d intravenous (i.v.) anti-D
Number of subjects: 27

Group type: COMPARATOR
Intervention: 50 microg/kg/d intravenous (i.v.) anti-D
Number of subjects: 27
Study: 9253562

Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms kg‐1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg kg‐1
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Droperidol 75 micrograms kg‐1 and Ondansetron 0.1 mg kg‐1
Number of subjects: 160

Group type: COMPARATOR
Intervention: NaCl as placebo
Number of subjects: 160
Study: 8310137

Group type: EXPERIMENTAL
Intervention: Conformal pelvic radiotherapy (dose levels of 30‐38 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conformal pelvic radiotherapy (dose levels of 56‐65 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conformal pelvic radiotherapy (general assessment)
Number of subjects: 0
Study: 3538914

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31575508

Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg every 8 weeks
Number of subjects: 3910

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks
Number of subjects: 3910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3910
Study: 31234547

Group type: EXPERIMENTAL
Intervention: Self-management intervention providing advice on work-recovery-rest balance, food and drink intake, and physical activity.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study: 28097317

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus 6 months of androgen deprivation therapy
Number of subjects: 157

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 157
Study: 26085515

Group type: EXPERIMENTAL
Intervention: HSF + DHA diet (3.45 g DHA/d and 0.5 g EPA/d)
Number of subjects: 82

Group type: COMPARATOR
Intervention: HSF diet
Number of subjects: 82
Study: 23663917

Group type: EXPERIMENTAL
Intervention: Tailored regimen (daily pills until three consecutive days bleeding triggers a 3‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Standard regimen (21 daily pills followed by a 7‐day pill‐free interval) of Microgynon 30® (ethinyl oestradiol 30 mcg, levonorgestrel 150 mcg)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Tailored regimen
Number of subjects: 503

Group type: COMPARATOR
Intervention: Standard regimen
Number of subjects: 503
Study: 21856336

Group type: EXPERIMENTAL
Intervention: Anodic tDCS (20 min, 1 mA) during intensive language training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham stimulation during intensive language training
Number of subjects: 3
Study: 20415935

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen arginate (PRE group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen arginate (POST group)
Number of subjects: 30
Study: 17847722

Group type: EXPERIMENTAL
Intervention: Thermal welding tonsillectomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 32
Study: 15197379

Group type: EXPERIMENTAL
Intervention: Single-task workers providing feeding assistance during mealtimes
Number of subjects: 0
Study: 11700188

Group type: EXPERIMENTAL
Intervention: Tissue coblation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard bipolar dissection
Number of subjects: 38
Study: 9207618

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 8424190

Group type: EXPERIMENTAL
Intervention: Suction curettage
Number of subjects: 357

Group type: COMPARATOR
Intervention: Conventional curettage
Number of subjects: 357